Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Process for making 5-azacytosine nucleosides and their derivatives

A kind of technology of azacytidine nucleoside compound and azacytidine nucleoside, which is applied in the field of preparation of 5-azacytidine nucleoside, which can solve the problem of difficult removal of tin, separation by difficult filtration steps, and not suitable for the synthesis of albino Zacitidine and decitabine, etc., to save time

Active Publication Date: 2011-10-12
SCINOPHARM TAIWAN LTD
View PDF6 Cites 17 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

According to Ionescu and Blumbergs [7] , this approach has several major disadvantages: First, it is difficult to remove tin from the API
Third, a difficult filtration step is required to separate the insoluble tin salts
This method requires aqueous handling, making it less suitable for the synthesis of azacitidine and decitabine

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Process for making 5-azacytosine nucleosides and their derivatives
  • Process for making 5-azacytosine nucleosides and their derivatives
  • Process for making 5-azacytosine nucleosides and their derivatives

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0087] Preparation of 2-[(trimethylsilyl)amino]-4-[(trimethylsilyl)oxy]-s-triazine(silyl 5-azacytosine)

[0088]

[0089] A mixture of 5-azacytosine (7.33 Kg), HMDS (33.9 Kg) and ammonium sulfate (0.44 Kg) was heated at reflux (about 115 to 135° C.) and stirred for 16 hours. After the reaction was complete, the slurry was cooled to 118°C, then filtered through a pad of celite and rinsed with HMDS (5.6 Kg). The silylated 5-azacytosine solution was cooled to 35°C, and the solution was cooled to 18°C, stirred at 18°C ​​for not less than 6.5 hours, and then filtered. The solid was washed twice with HMDS, 5.6 Kg each time, and dried under vacuum at ≤70° C. for 9.5 hours to obtain 14.19 Kg of white silyl 5-azacytosine (87%).

example 2

[0091] Coupling and deprotection of silyl 5-azacytosine to sugars

[0092]

[0093] At 55°C, 2-[(trimethylsilyl)amino]-4-[(trimethylsilyl)oxy]-s-triazine (4.5Kg), 1-O-acetyl-2 , a mixture of 3,5-tri-O-benzoyl-β-D-ribofuranose (8.8 Kg), anhydrous MeCN (34.6 Kg) and TfOH (600 g) was heated for 12.5 hours. The reaction mixture was cooled to 45 °C, DMSO (29 Kg) was added, and MeCN was evaporated under vacuum at an internal temperature of less than 50 °C until the solution was about 54 L. The solution was cooled to 23°C. MeOH (13.9 Kg) was added followed by a solution of 30% NaOMe in MeOH solution (2.5 Kg) previously diluted with MeOH (7.0 Kg). The solution was stirred at 23°C for 35 minutes. When the reaction was complete, MeOH (90.4 Kg) was added and the resulting slurry was stirred at 22° C. for 3 hours 10 minutes, then filtered and washed 3 times with 7.0 Kg of MeOH. Under vacuum, the filter cake was dried at less than 70°C for 9 hours and 20 minutes to obtain 3.2 Kg of ...

example 3

[0095] Purified Crude Azacitidine

[0096] Crude azacitidine (3.2 Kg) was dissolved in DMSO (11.8 Kg) at 20 to 40°C, filtered and the collected solids rinsed with DMSO (10.1 Kg). The filtrate was cooled to 20 to 25°C and MeOH (9.7 Kg) was added over a period of 30 minutes followed by azacitidine seed (30.6 g) and the mixture was stirred at 23°C for about 1 hour. Additional MeOH was added over a period of 4 hours 13 minutes and the mixture was stirred at 20 to 25 °C for at least 10 hours, filtered and washed 3 times with 10 Kg of MeOH. Under vacuum, the filter cake was dried at ≤70° C. for 33 hours to obtain 2.6 Kg of API grade azacitidine (86% yield based on crude azacitidine).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A process of synthesizing a 5-azacytosine nucleoside, such as azacitidine and decitabine, comprises coupling a silylated 5-azacytosine with a protected D-ribofuranose of formula in the presence of a sulfonic acid catalyst.

Description

[0001] Related applications [0002] This application claims priority to US Provisional Patent Application Serial No. 61 / 188,431, filed August 8, 2008. The entire contents of this patent are incorporated herein by reference. technical field [0003] The present invention relates to efficient industrial synthesis of 1-glycosyl-5-azacytosine (hereinafter referred to as 5-azacytosine nucleoside). The method of the present invention is particularly suitable for the preparation of 5-azacytidine nucleosides, such as 5-azacytidine (azacitidine (azacitidine)), 2'-deoxy-5-azacytidine (decitabine (decitabine)). It is well known that azacitidine and its deoxyribose derivative decitabine are suitable for the treatment of diseases, especially myelodysplastic syndrome (MDS). Background technique [0004] Examples of 5-azacytidine and methods for its synthesis have been previously reported. Azacitidine (also known as 5-azacytidine, 5-AC and Vidaza TM ) and its deoxyribose derivative ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07H19/12C07H1/00A01N43/04
CPCC07H13/04C07H13/08C07H19/12A61P35/00A61P43/00A61K31/7052C07H1/00A61L2300/416
Inventor 朱利安·保罗·汉史克张孝恒王龙虎陈勇发
Owner SCINOPHARM TAIWAN LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com